FIGURE 5.

The lesatropane-induced ERK1/2 activity and neuroprotective effects are partially dependent on PKC. PC12 cells were pretreated with 5 μg/ml chelerythrine 30 min before the addition of 0.01 μM lesatropane, then 1 mM glutamate. (A) PKC activity measurement by non-radioactive protein kinase assay. (B) ERK1/2 activation was determined by Western blotting. (C) Cell viability was quantified using the MTT assay after 48 h. * p<0.01 vs lesatropane group. Data represent the mean± S.E. of n=5 independent observations.